Abiprubart Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results And Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results And Recent Portfolio Execution
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United kingdomSanjk patelDrug administrationExchange commissionAmerican college of cardiology scientific sessionKiniksa pharmaceuticals ltdEuropean commissionRegeneron pharmaceuticals incAbiprubart phaseChief executive officerAmerican collegeCardiology scientific sessionRegeneron pharmaceuticalsFamilial cold autoinflammatory syndromeMuckle wells syndromeBreakthrough therapy

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Sanjk patelRachel frankGlobenewswire incExchange commissionKiniksa pharmaceuticals ltdAbiprubart phaseChief executive officerClinical trialSyndrome disease activity indexLeast squaresDisease activity scoreUsingc reactive proteinRheumatoid factor

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Rachel frankSanjk patelAmerican college of cardiology scientific sessionRegeneron pharmaceuticals incDrug administrationExchange commissionKiniksa pharmaceuticals ltdRoche groupGlobenewswire incEuropean commissionAbiprubart phaseChief executive officerRilonacept utilizationSteroid sparing paradigmRecurrent pericarditisCardiology scientific session

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST® 2023 net product revenue grew ~90% year-over-year to $233.1 million – – ARCALYST 2024 net product revenue expected to be $360 - $380 million – – Abiprubart Phase 2.

Rachel frankSanjk patelGlobenewswire incEuropean commissionDrug administrationKiniksa pharmaceuticals ltdExchange commissionRegeneron pharmaceuticals incAbiprubart phaseChief executive officerDisease activity scoreUsingc reactive proteinSecondary efficacy endpointMean differenceLeast squaresRheumatoid factor